Toutes les catégories
| Product Name | Description | Action |
|---|---|---|
| Sacituzumab govitecan | Trade Name : Trodelvy Target : TROP-2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 1014(First three quarters) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Risankizumab, Skyrizi, anticorps bispécifique, BI 655066, inhibiteur de l' interleukine / inhibiteur de l' IL-23, immunologie biologique, anticorps monoclonaux, n ° CAS 1612838-76-2 | Trade Name : Skyrizi Target : Bispecific antibody Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 13000~15000(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch ... |
|
| Téplizumab ,Téspire ,TSLP ,Anticorps monoclonal ,AMG 157 ,Biologique anti-TSLP ,Biologique respiratoire / Biologique pour l'asthme ,N° CAS 1572943-60-0 | Trade Name : Tezspire Target : TSLP Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 826(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Le dupilumab, le dupixent, le REGN668, l'inhibiteur du récepteur des interleukines, l'anticorps monoclonal, le CAS n° 1190264-60-8. | Trade Name : Dupixent Target : N/A Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 1340(First three quarters) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Hyaluronidase,Enzyme / Enzyme recombinante,Excipient biologique / Composant de la co-formulation biologique,N° CAS 9001-54-1 | Trade Name : N/A Target : N/A Molecular Type : Enzymes Sales in 2025 (Millions of USD) : 1300~1375(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Etanercept, Enbrel, Erelzi, Eticovo, produit biologique anti-TNF / inhibiteur du TNF, protéine de fusion, numéro CAS 185243-69-0 | Trade Name : Enbrel Target : N/A Molecular Type : Fusion Protein Sales in 2025 (Millions of USD) : 2300~2500(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Pertuzumab | Trade Name : Perjeta Target : N/A Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 2800(First three quartersestimate ) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch ... |
|
| Tocilizumab | Trade Name : Actemra Target : N/A Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 1280(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
